Inter-individual variation of DNA methylation and its implications for large-scale epigenome mapping by Bock, Christoph et al.
Published online 15 April 2008 Nucleic Acids Research, 2008, Vol. 36, No. 10 e55
doi:10.1093/nar/gkn122
Inter-individual variation of DNA methylation and its
implications for large-scale epigenome mapping
Christoph Bock
1,*, Jo ¨rn Walter
2, Martina Paulsen
2 and Thomas Lengauer
1
1Max-Planck-Institut fu ¨r Informatik and
2Universita ¨t des Saarlandes, FR 8.3 Biowissenschaften,
Genetik/Epigenetik, Saarbru ¨cken, Germany
Received January 20, 2008; Revised March 2, 2008; Accepted March 4, 2008
ABSTRACT
Genomic DNA methylation profiles exhibit substan-
tial variation within the human population, with
important functional implications for gene regula-
tion. So far little is known about the characteristics
and determinants of DNA methylation variation
among healthy individuals. We performed bioinfor-
matic analysis of high-resolution methylation pro-
files from multiple individuals, uncovering complex
patterns of inter-individual variation that are strongly
correlated with the local DNA sequence. CpG-rich
regions exhibit low and relatively similar levels of
DNA methylation in all individuals, but the sequential
order of the (few) methylated among the (many)
unmethylated CpGs differs randomly across individ-
uals. In contrast, CpG-poor regions exhibit sub-
stantially elevated levels of inter-individual variation,
but also significant conservation of specific DNA
methylation patterns between unrelated individuals.
This observation has important implications for
experimental analysis of DNA methylation, e.g. in
the context of epigenome projects. First, DNA
methylation mapping at single-CpG resolution is
expected to uncover informative DNA methylation
patterns for the CpG-poor bulk of the human
genome. Second, for CpG-rich regions it will be
sufficient to measure average methylation levels
rather than assaying every single CpG. We sub-
stantiate these conclusions by an in silico bench-
marking study of six widely used methods for DNA
methylation mapping. Based on our findings, we
propose a cost-optimized two-track strategy for
mammalian methylome projects.
INTRODUCTION
DNA methylation is the only epigenetic modiﬁcation that
directly targets the DNA, and it is an important
component of epigenetic regulation (1,2). In mammalian
genomes, DNA methylation is largely restricted to
cytosines in a CpG context, and the genomic regions that
harbor the highest density of CpG dinucleotides—known
as CpG islands (3,4)—exhibit the lowest levels of DNA
methylation. Through its ability to induce locally con-
densed chromatin structure, DNA methylation contributes
to gene regulation. Promoter hypermethylation is known
to cause stable silencing of associated genes and plays an
important role for both normal development (5) and
disease (6).
Because of its general relevance for gene regulation and
chromatin structure, experimental mapping of DNA
methylation patterns continues to be of high biological
and medical relevance, despite recent progress in predict-
ing DNA methylation computationally (7–9). Initial DNA
methylation mapping projects (see Bernstein et al. (10) and
Bock and Lengauer (11) for recent reviews) not only illu-
minate the complex distribution of DNA methylation in
the human genome, but also highlight the importance of
inter-individual variation among DNA methylation proﬁ-
les from diﬀerent individuals. As the impact of epigenetic
polymorphisms on gene expression and phenotypic traits
is well-established (12,13), DNA methylation variation is
potentially a major contributor to phenotypic variation in
humans.
Better understanding of inter-individual variation of
DNA methylation is desirable also from a practical point
of view. First, it is critical to know the range of DNA
methylation variation in healthy individuals in order to
conﬁdently detect aberrant methylation in diseased
patients. This point is exempliﬁed by the optimization
of cancer biomarkers for robustness and precision, during
which it is critical to select CpG dinucleotides that exhibit
small amounts of inter-individual variation within
the groups of cancer patients and controls, respectively,
but strong variation between the two groups (14).
Second, large-scale DNA methylation mapping initiatives
proﬁt from robust estimates of DNA methylation
variation, because such estimates provide a basis for
rational choice of required sample sizes, selection of
appropriate experimental methods and identiﬁcation
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In this study, we quantitatively analyze the character-
istics and determinants of DNA methylation variation
among healthy individuals, based on a large-scale and
high-resolution dataset originating from the Human
Epigenome Project (HEP) of the Sanger Institute and
Epigenomics AG (15). Furthermore, we use a combina-
tion of computational modeling and simulation in order to
benchmark current experimental methods for DNA
methylation mapping and to guide the strategy for
establishing mammalian reference methylomes. In parti-
cular, we ask whether the use of high-resolution mapping
methods is required and informative for all parts of the
human genome or whether cheaper medium-resolution
methods may be suﬃcient at least for certain parts of the
genome.
MATERIALS AND METHODS
Adataset ofhigh-resolution DNA methylation
profiles frommultiple individuals
As the basis for this study, we selected the HEP dataset
reported by Eckhardt et al. (15), because it is the largest
high-resolution, multi-individual dataset of DNA methy-
lation proﬁles that has been published to date. Brieﬂy,
Eckhardt et al. (15) combined direct Sanger sequencing of
bisulﬁte-converted DNA with a bioinformatic method for
deriving quantitative and high-resolution DNA methyla-
tion proﬁles from chromatograms. With this strategy, they
analyzed 2524 amplicons on human chromosomes 6, 20
and 22 in 12 diﬀerent tissues and 43 diﬀerent samples. Ten
samples belonging to three tissues (CD4+ T lymphocytes,
CD8+ T lymphocytes and melanocytes) originate from
single donors and were selected for our analysis, while the
remaining samples are pooled DNA from several indivi-
duals, which makes them less suitable for analyzing inter-
individual variation. For clarity, all results presented
in this article are based on CD4+ T lymphocyte data.
Comparable results were obtained for the other two
tissues as well as for the cross-tissue comparison of all 10
samples (data not shown).
The raw data were downloaded from http://www.
sanger.ac.uk/PostGenomics/epigenome/. To prepare for
further analysis, the diﬀerent record types (‘analysis’,
‘trace’ and ‘variation’) were merged by their identiﬁers,
and records corresponding to technical controls were
discarded. The analysis described here is based on the
second technical replicate, which contains more valid data
than the ﬁrst technical replicate. Averaging of the two
replicates was not an option because of incomplete
overlap, but the analyses described in this article were
repeated on the ﬁrst replicate and comparable results were
obtained. Amplicons with insuﬃcient data were removed,
giving rise to a dataset of 1705 amplicons. These
amplicons are on average 287bp long (ﬁrst to last assessed
CpG) with an SD of 85bp, and they comprise 16 CpGs,
on average. The majority (58%) of the amplicons overlap
with CpG islands according to the Gardiner–Garden
criteria (3) with repeat-masking and a quarter (25%)
overlap with more stringent bona ﬁde CpG islands (4).
Statistical analysis ofDNA methylation variation
among healthy individuals
Three complementary measures of inter-individual varia-
tion between DNA methylation proﬁles are used in this
study (deﬁned below): (i) pairwise deviation between high-
resolution proﬁles, (ii) deviation between mean and high-
resolution proﬁle and (iii) pairwise deviation between
means. These measures are calculated from pairwise
comparisons between DNA methylation proﬁles of non-
identical individuals, which are averaged separately for
each amplicon in the dataset. In the pairwise comparisons,
the root mean square deviation (RMSD) is used to assess
deviations between DNA methylation proﬁles of diﬀerent
individuals. The RMSD is more appropriate for this
purpose than the Pearson correlation coeﬃcient (which is
the other popular measure of similarity/deviation) because
DNA methylation levels are frequently constant within an
amplicon, in which case their SD becomes zero and the
correlation coeﬃcient is undeﬁned.
The pairwise deviation between high-resolution proﬁles
(v1) compares DNA methylation levels at every single
CpG, thereby assessing how similar or diﬀerent DNA
methylation proﬁles from unrelated individuals are at a
given amplicon. This measure is deﬁned by the following
formula (calculated separately for each amplicon), in
which m is the number of samples from diﬀerent
individuals, Pi and Pj are sets of CpG positions with
valid measurements for samples i and j, respectively, xi,k
and xj,k are the methylation levels measured at position k
in samples i and j, respectively, and n is the number of
positions in common between Pi and Pj:
v1 ¼
1
m  ð m   1Þ
X m
i¼1
X m
j¼1,j6¼i
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n
X
k2Pi\Pj
ðxi,k   xj,kÞ
2
s
:
The deviation between mean and high-resolution proﬁle (v2)
compares the mean methylation level of one individual
to the high-resolution DNA methylation proﬁle of
other individuals, thereby assessing how predictive the
mean amplicon methylation of one individual is for
the DNA methylation proﬁle of unrelated individuals.
This measure is deﬁned by the following formula, in
which one DNA methylation proﬁle is replaced by its
mean ð  xj ¼ 1= Pj
       P
k2Pj xj,kÞ:
v2 ¼
1
m  ð m   1Þ
X m
i¼1
X m
j¼1,j6¼i
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n
X
k2Pi\Pj
ðxi,k     xjÞ
2
s
:
The pairwise deviation between means (v3) compares the
mean amplicon methylation levels between a set of
individuals, ignoring the sequential order of methylated
and unmethylated CpGs. It is deﬁned by replacing the
remaining DNA methylation proﬁle in formula v2 by its
mean ð  xi ¼ 1= Pi jj
P
k2Pi xi,kÞ, giving rise to a formula that
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unrelated individuals:
v3 ¼
1
m  ð m   1Þ
X m
i¼1
X m
j¼1,j6¼i
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n
X
k2Pi\Pj
ð  xi     xjÞ
2
s
¼
1
m  ð m   1Þ
X m
i¼1
X m
j¼1,j6¼i
  xi     xj
       :
These three measures of inter-individual variation were
calculated for each valid amplicon in the HEP dataset.
Based on these data, we sought to derive a threshold on
DNA methylation that separates two distinct groups of
amplicons (high versus low methylation) such that the
between-group diﬀerences in terms of the three measures
of inter-individual variation are high. To that end, 99
potential thresholds were assessed (splitting the dataset
after each integer percentile) and the suitability of each
was tested using Multivariate ANalysis of VAriance
(MANOVA). Brieﬂy, MANOVA (16) ﬁnds the linear
combination of the three measures that is most discrimi-
native between the two amplicon groups (i.e. between
those amplicons exceeding the DNA methylation thresh-
old and those falling below the threshold), and it assesses
the signiﬁcance of this diﬀerence. Supplementary
Figure 1A shows a plot of the corresponding F-statistic
and Supplementary Figure 1B shows the DNA methyla-
tion histogram. Based on these two diagrams, it seems
plausible to split the groups at the 25th percentile,
corresponding to an 11.5% threshold on the amplicon’s
DNA methylation average. In terms of their character-
istics of inter-individual variation, the amplicons below
this threshold (ﬁrst quartile or top-25% of most unmethy-
lated amplicons) are strikingly distinct from the remaining
amplicons (P 10
 10).
In silico benchmarking of experimental methodsfor DNA
methylation mapping
To benchmark experimental methods for DNA methyla-
tion mapping in silico, we introduce the following
modiﬁcation of the v1 measure of inter-individual varia-
tion. The ﬁrst DNA methylation proﬁle is pre-processed
by a function that simulates experimental analysis, and
this pre-processed proﬁle is compared with the second
proﬁle (all simulation functions are deﬁned and explained
in Table 1, and an illustrative example is given in
Supplementary Figure 2). This way, we can assess how
well the simulated measurement for a particular experi-
mental method predicts the high-resolution DNA methy-
lation proﬁle of other individuals. Formally, these new
criteria vmethod (one per simulation function) are deﬁned
by the following formula, in which xi is the vector of
methylation levels of sample i at positions Pi, fmethod is the
simulation function and method is any of the identiﬁers in
Table 1, rightmost column (i.e. A1–G7):
vmethod ¼
1
m ðm 1Þ
X m
i¼1
X m
j¼1,j6¼i
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n
X
k2Pi\Pj
ðfmethodðxiÞk xj,kÞ
2
s
While this formula is a straightforward extension of the
described measures of inter-individual variation, the
choice of simulation functions in Table 1 may warrant
further discussion. Each simulation function computes the
expected DNA methylation measurement for a speciﬁc
experimental method on an amplicon with known
methylation proﬁle. The simulation functions are modeled
after the known mechanisms and experimental constraints
of the underlying experimental methods. Diﬀerent var-
iants of the same method are included in order to assess the
sensitivity to diﬀerent experimental conditions. When
constructing these simulation functions, we relied not
only on our own practical experiences and on literature
research, but also consulted with domain experts within the
EU Network of Excellence ‘The Epigenome’, in order to
verify that the design of the rules and the choice of
parameters were appropriately modeling the experiment
under optimal conditions. In addition, we validated that
thesensitivity of ourresults to thechoice ofparameters was
generally low (see Results section). Therefore, while a
comprehensive empirical evaluation is not feasible in the
absence of a large-scale experimental benchmarking
dataset,weconcludethattherulesinTable1aresuﬃciently
accurate and reliable for the purposes of this study.
Bioinformatic analysis andprediction of DNA methylation
variation among healthyindividuals
For quantitative analysis and prediction of the improve-
ment in accuracy achievable by high-resolution methyla-
tion mapping of a speciﬁc amplicon, we deﬁned the
high-resolution improvement h as the diﬀerence between
the inter-individual deviation calculated for medium-
resolution MeDIP (vD1) and high-resolution bisulﬁte
sequencing (vF1), i.e. h ¼ vD1   vF1. Amplicons with high
values exhibit inter-individually similar DNA methylation
patterns while amplicons with low values do not (but may
still exhibit similar average methylation levels across
individuals).
The EpiGRAPH web service (http://epigraph.mpi-inf.
mpg.de/WebGRAPH/) was used to test a large number
of genomic attributes for their ability to distinguish
between amplicons with high versus low high-resolution
improvement. To that end, two lists of amplicons (the top
and the bottom quartile in terms of the high-resolution
improvement) were uploaded into EpiGRAPH, and
EpiGRAPH was used to test 845 genomic attributes for
signiﬁcant diﬀerences between the two lists. Signiﬁcance
was assessed by pairwise Wilcoxon tests, a global
signiﬁcance threshold of 5% was chosen and the highly
conservative Bonferroni method was applied to correct for
multiple testing. A more detailed description of the
EpiGRAPH prediction pipeline is given elsewhere [(4,7),
and Bock et al., in preparation].
Linear regression models were constructed to predict
the dependent variable h (high-resolution improvement)
from diﬀerent subsets of independent variables. Both
forward selection and backward selection were used to
identify the most appropriate combination of independent
variables. The following independent variables were
included in the analysis: mean and SD of amplicon
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expected ratio, calculated as in the deﬁnition of CpG
islands (3); the relative frequency of three DNA sequence
patterns (CG, CA and GC); the percent overlap with
traditional and bona ﬁde CpG islands, based on a recent
study that derived an improved annotation of CpG islands
for the human genome (4); the degree of promoter activity
derived from large-scale experimental data on transcrip-
tion initiation events (17); and the degree of transcrip-
tional activity derived from the frequency of overlap with
human ESTs from GenBank. The ﬁrst four of these
attributes were calculated directly from the HEP dataset
and all other attributes were calculated by the EpiGRAPH
web service. All statistical analyses were performed using
the R-statistics software (www.r-project.org/).
RESULTS
DNA methylation profiles showcomplex patterns
of variation among healthyindividuals
Toward a better understanding of DNA methylation
variation in healthy individuals, we deﬁned three measures
Table 1. Functions for simulating experimental methods of DNA methylation mapping in silico
Method name References Method type Comment Simulation function
Diﬀerential methyl-
ation hybridization
(DMH)
Huang et al. (28)
Khulan et al. (29)
Pﬁster et al. (30)
Methylation-speciﬁc
fodigestion, qualitative
Quantiﬁcation is diﬃ-
cult due to diﬀerent
oligomer aﬃnities and
DNA melting
temperatures
A1: HiMeth if #CpGpattern* & meth 50%  3
A2: HiMeth if #CpGpattern* & meth 50%  2
A3: HiMeth if #CpGpattern* & meth 50%  1
*pattern in {ACGT, CCGC, CCGG, GCGC}
Sequencing of methyl-
ation- speciﬁc diges-
tion products
Rollins et al. (31) Methylation-speciﬁc
digestion, quantitative
Quantiﬁcation is pos-
sible if sequencing
depth is high
B1: Proﬁle(all CpGs in ACGT patterns)
B2: Proﬁle(all CpGs in CCGC patterns)
B3: Proﬁle(all CpGs in CCGG patterns)
B4: Proﬁle(all CpGs in GCGC patterns)
B5: Proﬁle(all CpGs in all four patterns)
Methyl-DNA immu-
noprecipitation
plus tiling microarrays
(MeDIP-chip)
Weber et al. (32)
Weber et al. (23)
Zhang et al. (33)
Zilberman et al. (34)
Immunoprecipitation,
qualitative
Quantiﬁcation is diﬃ-
cult due to diﬀerent
oligomer aﬃnities and
DNA melting
temperatures
C1: HiMeth if #CpGmeth 67%  4*
C2: HiMeth if #CpGmeth 50%  3*
C3: HiMeth if #CpGmeth 33%  2*
*minimum value per 200bp
Sequencing of MeDIP-
generated DNA
libraries (MeDIP-seq)
Established at several
labs, e.g. at the Max
Planck Institute for
Molecular Genetics
(H. Lehrach, personal
communication)
Immunoprecipitation,
quantitative
Quantiﬁcation is pos-
sible if the enrichment
is statistically cor-
rected for local diﬀer-
ences in CpG density
D1: Value(Mean(all CpGs))
D2: Value(Median(all CpGs))
Microarray hybridiza-
tion of bisulﬁte-con-
verted DNA
Adorjan et al. (35)
Gitan et al. (36)
Kimura et al. (37) Yan
et al. (38)
Bisulﬁte conversion,
qualitative
Quantiﬁcation has
been attempted but is
often unreliable
E1: HiMeth if mean (all CpGs)   67%
E2: HiMeth if mean (all CpGs)   50%
E3: HiMeth if mean (all CpGs)   33%
Direct sequencing of
bisulﬁte-converted
DNA
Eckhardt et al. (15)
Lewin et al. (19)
Rakyan et al. (39)
Bisulﬁte conversion,
quantitative
Quantitative and
applicable to either all
CpGs of an amplicon
(by Sanger
sequencing) or to a
subset (by primer
extension or
pyrosequencing)
F1: Proﬁle(all CpGs)
F2–F5: Proﬁle(1 to 4 random CpGs)
F6: Proﬁle(center CpG)
F7: Proﬁle(ﬁrst and last CpG)
F8: Proﬁle(CpGs at positions 1/3 and 2/3)
F9: Proﬁle(ﬁrst, center and last CpG)
F10–F20: Proﬁle (0%, 10%,..., 100% of
CpGs, rounded to the next integer value
and randomly selected)
Rule-based guess (for
comparison as a nega-
tive control)
None No DNA methylation
data is taken into
account
Worst-case baseline
that any method
should compare favor-
ably with
G1: Value(0% methylated)
G2: Value(50% methylated)
G3: Value(100% methylated)
G4: Value(LowMeth)
G5: Value(MeanMeth)
G6: Value(HiMeth)
G7: Proﬁle(random methylation values)
This table summarizes the experimental methods for DNA methylation mapping that are covered in this study, and it describes the functions that
were constructed to simulate them in silico (rightmost column). The simulation functions are written in an abbreviated notation, as if-clauses,a s
proﬁle statements or as value assignments. (i) For if-clause rules, a methylation constant named HiMeth is assigned to all CpGs in amplicons
identiﬁed as high-methylation and a constant named LowMeth is assigned to all CpGs in low-methylation amplicons. We set HiMeth=80.39% and
LowMeth=13.13%, which are the mean methylation levels of all amplicon that exceed or fall below 50% methylation, respectively, in the HEP
dataset. (ii) For proﬁle statements, a subset of CpGs that fulﬁll the condition in brackets are selected and the methylation values of all unselected
CpGs are determined by interpolation or extrapolation. (iii) Value assignments are a special case of proﬁle statements, in which no CpGs are selected
and the methylation values of all CpGs are set to a constant value (MeanMeth=56.91% for the HEP dataset). #CpGcondition stands for the number
of CpGs in the amplicon that fulﬁll the condition. The source code implementing each of these rules is available on request (written in the Python
programming language).
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dataset (see Materials and Methods section for details).
Each measure captures a diﬀerent aspect of inter-
individual variation. The pairwise deviation between high-
resolution proﬁles assesses the deviation between DNA
methylation proﬁles from diﬀerent individuals by sum-
ming over methylation diﬀerences of individual CpGs. Its
value is low when all proﬁles for an amplicon are similar in
terms of both their overall DNA methylation levels and
their DNA methylation patterns. The pairwise deviation
between means measures inter-individual diﬀerences of the
average amplicon methylation. Its value is low when all
DNA proﬁles share a similar mean, irrespective of the
exact distribution and sequential order of methylated and
unmethylated CpGs. The deviation between mean and high-
resolution proﬁle is a hybrid of the other two measures. Its
value is low when DNA methylation proﬁles show little
deviation from the mean of other proﬁles. Figure 1
illustrates the diﬀerent behavior of these measures for two
amplicons with artiﬁcially designed DNA methylation
proﬁles.
Using these three measures we analyzed whether the
characteristics of inter-individual variation diﬀer between
amplicons with low versus high DNA methylation levels
(Figure 2, left). The results show that—by all three
measures—the inter-individual variation of DNA methy-
lation is lower for unmethylated amplicons than for
methylated amplicons. This eﬀect is strongest for the
pairwise deviation between means (61% reduction), but
also highly signiﬁcant for the other measures (P<10
 20 in
all cases). This observation was not unexpected and could
be explained by overlap with CpG islands, which are well-
known to be stably unmethylated in a wide range of
tissues. To test the role that CpG islands may play for this
eﬀect, we grouped amplicons by their overlap with bona
ﬁde CpG islands (4) and repeated the analysis (Figure 2,
right). The results were similar, although the reduction of
variance was less pronounced in the amplicons over-
lapping with bona ﬁde CpG islands than in the experi-
mentally unmethylated CpG islands. We also repeated this
analysis using the Gardiner–Garden deﬁnition of CpG
islands (3) and observe further dilution of the eﬀect
(Supplementary Figure 3), consistent with previous
reports suggesting that traditional CpG island criteria
give rise to a large number of false positives (4,18).
Beyond these results, which conﬁrm and quantify
previous observations, we found a second major diﬀerence
between methylated and unmethylated amplicons. For
methylated amplicons (and also for amplicons outside
CpG islands), the pairwise deviation between high-
resolution proﬁles is substantially lower than the deviation
between mean and high-resolution proﬁle. In contrast,
diﬀerences are small for unmethylated amplicons and for
amplicons overlapping with bona ﬁde CpG islands
(Figure 2). Importantly, this is not a side eﬀect of the
smaller scope for variation available to amplicons that
were selected by their low DNA methylation averages,
which is shown by plotting the top-25% most highly
unmethylated amplicons versus the top-25% most highly
methylated amplicons (to which similar constraints apply)
or the amplicons with an average methylation below 25%
versus the amplicons with an average methylation above
75% (Supplementary Figure 4). In both cases, the
diﬀerence of deviation between mean and high-resolution
proﬁle minus pairwise deviation between high-resolution
proﬁles is consistently higher in methylated amplicons
than in unmethylated amplicons.
These results indicate a qualitative diﬀerence in the
characteristics of inter-individual variation of DNA
methylation depending on the average level of DNA
methylation and the CpG density (see Figure 1 for
illustration). Methylated amplicons and amplicons outside
CpG islands exhibit a high degree of inter-individual
variation, but they also exhibit signiﬁcant conservation of
speciﬁc DNA methylation patterns between individuals,
which is evident from the fact that the predictiveness
across individuals increases when high-resolution proﬁles
are compared. In contrast, in unmethylated amplicons and
CpG islands the overall degree of inter-individual varia-
tion is substantially lower, but the high-resolution proﬁle
of one individual is not more predictive of other
individuals’ DNA methylation than its mean methylation
level. Hence, we can regard the DNA methylation patterns
of methylated and CpG-poor amplicons as informative at
high resolution, while the average methylation level may
suﬃce to characterize DNA methylation at unmethylated
amplicons and CpG islands.
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Figure 1. DNA methylation variation among healthy individuals
(schematic ﬁgure). This ﬁgure displays artiﬁcial DNA methylation
data for two amplicons with two unrelated samples/proﬁles each, which
were designed to illustrate the eﬀect of the three measures of inter-
individual variation used in this study. The typical amplicon with high
overall methylation (blue proﬁles, top) has a relatively high pairwise
deviation between means (v3) and a pairwise deviation between high-
resolution proﬁles (v1) that is substantially lower than the deviation
between mean and high-resolution proﬁle (v2), which is reﬂected in a
substantial correlation between the rising and falling of the DNA
methylation proﬁle curves over the length of the amplicon. In contrast,
the typical amplicon with low overall methylation (red proﬁles, bottom)
has a low pairwise deviation between means (v3) and similar values for
pairwise deviation between high-resolution proﬁles (v1) and deviation
between mean and high-resolution proﬁle (v2), indicating that the
ﬂuctuations in the proﬁles are not inter-individually conserved and
presumably random.
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methylation mapping is most informative outside
CpG islands
The diﬀerent characteristics of inter-individual variation
have important implications for rational choice of
experimental methods for DNA methylation mapping:
High-resolution mapping (e.g. by bisulﬁte sequencing)
would be required outside CpG islands, while methods
that assess average methylation levels (e.g. MeDIP) were
suﬃcient for CpG islands. To substantiate this conclusion,
we conducted a comprehensive in silico benchmarking
study of six widely used experimental methods for DNA
methylation mapping. This benchmarking is based on the
assumption that DNA methylation proﬁles are only
informative to the degree to which they are conserved
between individuals (see Discussion section for critical
assessment), and it adheres to a straightforward protocol:
For each amplicon in the HEP dataset and all pairs of
(non-identical) DNA methylation proﬁles derived from
diﬀerent individuals, we compared how well a simulated
measurement—calculated from the ﬁrst proﬁle—predicts
the second DNA methylation proﬁle. The key point is that
the measurement derived from the ﬁrst proﬁle is calculated
in a way that models the experimental characteristics of
diﬀerent methods for DNA methylation mapping
(Table 1). For example, for method C2 (qualitative
immunoprecipitation), an amplicon is considered methy-
lated if more than three CpGs per 200bp exhibit DNA
methylation levels above 50%. For method B3 (quantita-
tive analysis of HpaII methylation-sensitive restriction
libraries), the simulated measurement is calculated by
assigning the known methylation levels to all CpGs that
overlap with the enzyme’s recognition sites (CCGG), while
the methylation levels of all remaining CpG dinucleotides
are determined by interpolation or extrapolation. This
way, the benchmarking assesses how accurately diﬀerent
experimental methods map inter-individually stable DNA
methylation.
The results calculated over all amplicons (Figure 3)
show that high-resolution mapping by bisulﬁte sequencing
(method F1) gives rise to the lowest inter-individual
deviation (vF1=0.164). Therefore, a substantial number
of CpGs in the genome must exhibit inter-individually
stable DNA methylation patterns, which can be
detected only by high-resolution bisulﬁte sequencing.
However, quantitative immunoprecipitation (method
D1) follows relatively closely behind, with an average
deviation that is 16% higher than that of bisulﬁte
sequencing. Qualitative methods—which test whether the
DNA methylation in a genomic region exceeds a speciﬁc
threshold rather than measuring its exact value—tend to
perform worse than quantitative methods. The best one
(method E3) results in an average deviation that is 36%
worse than that of bisulﬁte sequencing. This, however, is
still substantially better than random guessing (method
G7), which would lead to average deviations that are more
than three times worse than for bisulﬁte sequencing. Two
additional observations are worth highlighting. First,
alternative rules for the same experimental method
(listed in the same rows in Table 1) perform similarly.
This is particularly evident for the method groups A1–A3,
C1–C3, D1–D2 and E1–E3, indicating that our results
are robust regarding the choice of parameters for
these rules. Second, for those methods that interrogate
several individual CpGs to assess an amplicon’s methyla-
tion status, careful selection of representative CpGs
can increase performance. For example, selecting the
Other amplicons (meth.>0.115) Top-25% unmethylated amplicons
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Figure 2. Eﬀect of average amplicon methylation (left) and overlap with bona ﬁde CpG islands (right) on inter-individual variation of DNA
methylation. This ﬁgure shows the means of the three measures of DNA methylation variation as bar plots. In the left panel, values are reported
separately for the top-25% most unmethylated amplicons with an average amplicon methylation of <11.5% (this threshold is motivated in the
Materials and Methods section) and for the remaining 75% of amplicons. In the right panel, distinction is made between amplicons that overlap with
a bona ﬁde CpG island (4) and those that do not. In both cases, error bars represent 95% conﬁdence intervals under the assumption of normal
distribution and the P-values in the legends are based on two-sample, two-sided, t-tests between the group means for each measure.
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randomly selecting two CpGs (method F3) performs
worse than the more representative selection of the
two CpGs that are located most closely to positions one-
third and two-thirds relative to the amplicon length
(method F8).
Having established this in silico prediction setup, we
could test our initial hypothesis that bisulﬁte sequencing
(method F1) performs better than, for example, MeDIP
(method D1), but does so only for amplicons that
exhibit substantial methylation and do not overlap
with CpG islands. The results strongly support our
hypothesis (Supplementary Figures 5 and 6). For ampli-
cons with substantial methylation (the same threshold is
used as in Figure 2), as well as for amplicons that do not
overlap with a bona ﬁde CpG island, MeDIP performs
almost 20% worse than bisulﬁte sequencing. In contrast,
for amplicons overlapping with a bona ﬁde CpG island the
diﬀerence is less than 3%, and for the most unmethylated
amplicons MeDIP performs even better than bisulﬁte
sequencing (by 11%)—arguably because it averages out
uninformative ﬂuctuations.
The accuracy improvement of high-resolution methylation
mapping canbe predicted fromthe DNA sequence
Up to this point, we have used the overlap with bona
ﬁde CpG islands as a sequence-based criterion to
discriminate amplicons for which measuring average
methylation levels is suﬃcient from those requiring high-
resolution mapping. However, a priori it is not clear that
this criterion provides the most accurate discrimination.
To put the identiﬁcation of regions that beneﬁt from
high-resolution mapping onto a more systematic basis, we
applied the following two-step process. First, we used the
publicly available EpiGRAPH web service (http://
epigraph.mpi-inf.mpg.de/WebGRAPH/) to obtain a
broad basis of potentially predictive attributes. Second,
for a selection of highly signiﬁcant attributes from the
EpiGRAPH analysis, we constructed linear regression
models that quantitatively predict the high-resolution
improvement, which we deﬁne as the diﬀerence
between the inter-individual deviation for simulated
medium-resolution MeDIP and simulated high-resolution
bisulﬁte sequencing.
A total of 845 genomic attributes were included in the
EpiGRAPH analysis, each belonging to one of the
following attribute groups: DNA sequence, DNA struc-
ture, repetitive DNA, chromosome organization, evolu-
tionary history, population variation, genes, regulatory
regions, transcriptome, epigenome and chromatin struc-
ture. Of these attributes, 96 were found to be signiﬁcantly
diﬀerent between amplicons with high versus low high-
resolution improvement (Supplementary Table 1). We
selected seven highly signiﬁcant attributes for in-depth
analysis, namely the relative frequency of the DNA
sequence patterns CG, CA and GC, the percent overlap
with traditional and bona ﬁde CpG islands, a quantitative
measure of promoter activity (CAGE tag frequency) and a
quantitative measure of transcriptional activity (EST
overlap frequency). Together with the mean and SD of
amplicon methylation as well as the GC content and CpG
observed versus expected ratio, this gave rise to a list of
11 independent variables, which we assessed for their
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Figure 3. Benchmarking results for experimental mapping of DNA methylation. This ﬁgure displays the results of in silico benchmarking of diﬀerent
DNA methylation mapping methods for all amplicons. The y-axis shows vmethod values for all experimental methods included in this study (A1–F9,
described in Table 1) and for seven negative controls, which are based on guessing rules rather than on experimental data (G1–G7, described in
Table 1). The standard boxplot format is used (boxes show center quartiles, whiskers extend to the most extreme data point which is no more than
1.5 times the interquartile range from the box) and outliers are hidden.
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(the dependent variable). Initially, we calculated pairwise
Pearson correlation coeﬃcients between the independent
and dependent variables (Table 2), highlighting substan-
tial correlation not only between the independent and
dependent variables, but also among the independent
variables.
We therefore used the statistical framework of linear
regression to control for correlations among the indepen-
dent variables and to derive a prediction model for the
high-resolution improvement. Using feature selection
(both forward and backward selection gave the same
results), we determined the optimal combination of
independent variables, and the following regression
model was calculated as an optimal linear predictor of
high resolution improvement:
hi ¼ 0:3202   ai   0:0463   bi   0:0264   ci þ 0:0102   di:
In this formula, hi stands for the high-resolution
improvement of amplicon i, ai is the SD of amplicon
methylation, bi the GC content, ci the CpG observed
versus expected ratio and di the percent overlap with
traditional CpG islands (calculated on the repeat-masked
genome). This regression model gives rise to a residual
standard error of SE=0.0611 and an adjusted correlation
coeﬃcient of r=0.48, and is highly signiﬁcant
(P<10
 10). Supplementary Figure 7 shows a scatter
plot comparing the model’s prediction with the observed
high-resolution improvement, indicating that the predic-
tion accuracy is high for low values of hi and decreases
substantially for high values of hi, due to high variance
among the observed values.
Prediction of high-resolution improvement facilitates
cost-efficient DNA methylation mapping
Finally, we asked whether prediction models could be
used prospectively, to help decide which amplicons require
high-resolution analysis (e.g. by bisulﬁte sequencing) and
for which amplicons it would be suﬃcient to measure their
average methylation level (e.g. by cost-eﬃcient MeDIP
analysis). We stipulated that the second alternative would
be acceptable and suﬃcient only if the risk is less than 5%
that a substantial loss of accuracy is incurred for a speciﬁc
amplicon. Based on Lewin et al. (19), who report a mean
absolute error of 14 percentage points for CpG methyla-
tion levels determined by bisulﬁte sequencing, we speak of
a substantial loss of accuracy if the high-resolution
improvement exceeds 0.14.
The goal then was to predictively identify as many
amplicons as possible that exhibit a low high-resolution
improvement, while not exceeding a false positive rate of
5%. To that end, we derived a new linear regression
model that does not include the SD of amplicon
methylation (this value is typically unknown when
planning experimental mapping of DNA methylation).
After feature selection, the following regression model was
Table 2. Correlation between high-resolution improvement and its potential predictors
High-
resolution
improve-
ment 
Mean
amplicon
methyla-
tion 
GC
content
Frequency
of CG
pattern
 
High-resolution im-
provement 
0.18 0.47  −0.22 −0.25 0.14 −0.19 −0.19 −0.20 −0.14 −0.03
Mean amplicon me-
thylation 
0.27 −0.37 −0.35 -0.55  −0.35 −0.03
SD of amplicon 
methylation  −0.27 −0.39 0.24 −0.37 −0.36 −0.21 −0.01
GC content  0.26 −0.28 0.27 0.04
expected ratio  0.36 0.30
Frequency of CG 
pattern  0.02
Frequency of CA
pattern  −0.20 -0.54  −0.30 −0.01
Frequency of GC
pattern  0.36 0.30 0.00
tional CpG islands  0.26 0.03
fide CpG islands  0.35 0.02
0.06
Frequency of overlap 
with human ESTs 1.00 
Pearson
correlation
SD of
amplicon
methyla-
tion 
CpG ob-
served versus
expected
ratio
Frequency
of CA
pattern
Frequency
of GC
pattern
Overlap
with tradi-
tional CpG
islands
Overlap
with bona
fide CpG
islands
Frequency
of tran-
scription
initiation
Frequency
of overlap
with hu-
man ESTs
 
1.00 0.47 −0.17
1.00 −0.51 −0.58 0.58 −0.55 −0.68
1.00 −0.42 −0.29
1.00 0.74 0.83 0.54 0.40
CpG observed versus 1.00 0.80 −0.65 0.71 0.30 0.01
1.00 −0.62 0.74  0.78 0.63  0.40
1.00 −0.54 −0.30
1.00 0.51
Overlap with tradi- 1.00 0.60
Overlap with bona  1.00
Frequency of tran-
scription initiation  1.00
1.00
This table displays pairwise Pearson correlation coeﬃcients for the accuracy improvement of high-resolution methylation mapping (ﬁrst row) and
several potential factors of inﬂuence. Orange (light) boxes mark strong positive correlation and blue (dark) boxes mark strong negative correlation.
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ei   0:0167 fi, in which ei stands for the relative frequency
of sequence pattern CA, fi for the percent overlap with
bona ﬁde CpG islands and the other variables are as
above. The accuracy of this model is lower than the
previous one (SE=0.0671 and r=0.26), but it is still
highly signiﬁcant (P<10
 10). Next, the threshold on the
predicted high-resolution improvement was chosen such
that no more than 5% of amplicons below this threshold
exhibit an observed high-resolution improvement of 0.14.
This calculation resulted in a threshold value of 0.0358,
selecting 1118 out of 1705 amplicons (65.6%) for which
high-resolution analysis is highly unlikely to provide
substantially improved accuracy over (cheaper) analysis of
average methylation levels.
DISCUSSION
This study analyzes inter-individual stability and variation
of DNA methylation proﬁles among healthy individuals.
Using statistical methods we could show that the DNA
methylation state of CpG-rich regions is exhaustively
characterized by their average methylation levels, while
high-resolution DNA methylation patterns are informa-
tive only in regions with low CpG density (high-resolution
patterns are considered informative if they improve
prediction accuracy when comparing DNA methylation
across individuals). A plausible biological explanation
would be that above a critical CpG density, neighboring
CpGs inﬂuence each other’s DNA methylation states so
strongly that individual CpGs cannot stably maintain
DNA methylation states deviating from those of their
neighbors. Biochemically, this could be achieved by
methylation-speciﬁc enhancement or repression of DNA
methyltransferase activity, a mechanism that has been
proposed to contribute to spreading of DNA methylation
(20). In contrast, individual CpGs in CpG-poor regions
lack this pressure from neighboring CpGs, and other
eﬀects—such as the local DNA sequence environment (21)
or transcription factor binding (22)—are likely to deter-
mine their DNA methylation states. From a systems point
of view, we suggest that CpG islands may act as emergent
and bistable epigenetic switches, in which multiple CpGs
collectively maintain a CpG-island-wide ‘on’ or ‘oﬀ’ state.
This concept is consistent with experimental data, includ-
ing the bimodal distribution of promoter methylation
observed in normal cells (23) and the fact that entire CpG
islands, rather than single CpGs, become aberrantly
methylated in cancer (24). It is also supported by two
recent in silico studies, which showed that co-operativity
among neighboring CpGs (25) or spatially close nucleo-
somes (26) is required for a genomic region to function as
a bistable epigenetic switch.
Based on our statistical results, we also considered the
practical implications for experimental analysis of DNA
methylation. Through the combination of computational
simulation and benchmarking across unrelated individ-
uals, we could show that in CpG-poor genomic regions,
high-resolution methods such as bisulﬁte sequencing
perform substantially better than medium-resolution
methods such as MeDIP. In contrast, both methods
perform similarly for CpG-rich genomic regions and CpG
islands, owing to high ﬂuctuation of the sequential order
of methylated and unmethylated CpGs in these regions.
We derived a linear classiﬁer for predicting which genomic
regions beneﬁt from bisulﬁte sequencing and for which
regions MeDIP is suﬃcient. To highlight the potential cost
savings arising from these results, we brieﬂy sketch how
the classiﬁer could inﬂuence a HEP-like project planned
today: Assume that half of the total project costs are
variable and proportional to the number of amplicons
analyzed. Furthermore, assume that it is four times as
expensive to assess all CpGs in an amplicon (by Sanger
sequencing of bisulﬁte-converted DNA) than to assess an
amplicon’s average methylation level (e.g. by MeDIP).
Our predictions would enable us to apply cheap methods
to roughly two-thirds (65.6%) of all HEP amplicons (see
Results section), such that only 5% of these would have
beneﬁted signiﬁcantly from costly high-resolution analysis
(i.e. the high-resolution improvement would be <0.14 for
95% of all amplicons). This would give rise to savings of
25% in terms of overall project costs, compared with the
indiscriminate high-resolution strategy used in the HEP.
Alternatively, these savings would permit the analysis of
50% more samples at the same overall project costs
(assuming that non-proportional costs are unaﬀected by
the increased throughput).
It is, however, important to keep several limitations of
our analysis in mind. First, all results are currently based
on a single, albeit large, dataset and should be further
validated on data obtained in diﬀerent labs, potentially
with diﬀerent methods and for a larger number of
samples. Second, because the HEP dataset was generated
using direct sequencing rather than sequencing of clones,
we were unable to assess the degree of variation within a
single sample. Third, because the HEP dataset uses only a
single sample per individual, we cannot exclude that
a substantial percentage of the observed inter-individual
diﬀerences may also be present between diﬀerent samples
of the same individual, e.g. as a result of tissue
heterogeneity. Fourth, our simulation rules compute the
expected DNA methylation measurement under optimal
conditions, ignoring aspects such as robustness with
respect to varying DNA quality or minor variation in
the experimental protocol. Hence, the benchmarking
results should be regarded as principal limitations rather
than concrete technical limitations for a particular
protocol and lab. Fifth, our assumption that those high-
resolution DNA methylation patterns ﬂuctuating ran-
domly between unrelated individuals are uninformative
and can be replaced by their mean holds true only when
the goal is to make generalizable claims about DNA
methylation patterns in a particular genomic region. This
is obviously the case in large-scale epigenome projects
aimed at the establishment of references maps of DNA
methylation, and also for most cancer epigenetics and
biomarker discovery projects. However, this assumption is
less appropriate when analyzing epigenetic regulation in a
single cell: a single methylated CpG may well be
functional, e.g. preventing a transcription factor from
binding to the DNA, even if it is not inter-individually
conserved.
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ﬁrst quantitative basis for strategic decision making in
large-scale DNA methylation mapping. Combining all of
our observations, we propose the following cost-optimized
two-track strategy for mammalian methylome projects:
On the one hand, DNA methylation at all CpG islands
(or more accurately: at all CpG-rich regions predicted by
the classiﬁer that is described in the Results section)
should be analyzed in a large number of individuals, in
order to quantify the degree of epigenetic variation within
human populations. For these experiments, a cost-eﬃcient
medium-resolution method such as MeDIP is suﬃcient,
since our results show that the methylation state of CpG
islands is exhaustively characterized by their average
methylation levels. On the other hand, in a smaller
number of individuals the entire genome—consisting
mostly of CpG-poor regions—should be analyzed by
high-throughput bisulﬁte sequencing (27), in order to
provide a basis for assessing which of these CpGs play a
functional role in gene regulation or chromatin structure
formation. This two-track strategy contrasts with the
naı¨ve approach of mapping DNA methylation at high
resolution where CpG density is high and at low
resolution where their density is low, which underlines
the relevance of computational analysis for informed
planning of epigenome projects.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We would like to thank Jo ¨ rn Lewin for help with the data
format used by the Human Epigenome Project, Florian
Eckhardt, Vardhman Rakyan and Jo ¨ rg Rahnenfu ¨ hrer
for interesting discussions and Joachim Bu ¨ ch as
well as Konstantin Halachev for technical support.
Furthermore, we acknowledge the advice from multiple
researchers involved in the EU Network of Excellence
‘The Epigenome’, which proved very helpful when
devising realistic rules for simulating experimental DNA
methylation mapping in silico. This work was conducted
within the context of the EU Network of Excellence
‘Biosapiens’ (LSHG-CT-2003-503265) and the EU
Network of Excellence ‘The Epigenome’ (LSHG-CT-
2004-503433). Funding to pay the Open Access publica-
tion charges for this article was provided by the Max
Planck Society.
Conﬂict of interest statement. None declared.
REFERENCES
1. Bird,A. (2002) DNA methylation patterns and epigenetic memory.
Genes Dev., 16, 6–21.
2. Weber,M. and Schu ¨ beler,D. (2007) Genomic patterns of DNA
methylation: targets and function of an epigenetic mark. Curr. Opin.
Cell Biol., 19, 273–280.
3. Gardiner-Garden,M. and Frommer,M. (1987) CpG islands in
vertebrate genomes. J. Mol. Biol., 196, 261–282.
4. Bock,C., Walter,J., Paulsen,M. and Lengauer,T. (2007) CpG island
mapping by epigenome prediction. PLoS Comput. Biol., 3, e110.
5. Reik,W. (2007) Stability and ﬂexibility of epigenetic gene regulation
in mammalian development. Nature, 447, 425–432.
6. Feinberg,A.P. (2007) Phenotypic plasticity and the epigenetics of
human disease. Nature, 447, 433–440.
7. Bock,C., Paulsen,M., Tierling,S., Mikeska,T., Lengauer,T. and
Walter,J. (2006) CpG island methylation in human lymphocytes is
highly correlated with DNA sequence, repeats and predicted DNA
structure. PLoS Genet., 2, e26.
8. Das,R., Dimitrova,N., Xuan,Z., Rollins,R.A., Haghighi,F.,
Edwards,J.R., Ju,J., Bestor,T.H. and Zhang,M.Q. (2006)
Computational prediction of methylation status in human genomic
sequences. Proc. Natl Acad. Sci. USA, 103, 10713–10716.
9. Fang,F., Fan,S., Zhang,X. and Zhang,M.Q. (2006) Predicting
methylation status of CpG islands in the human brain.
Bioinformatics, 22, 2204–2209.
10. Bernstein,B.E., Meissner,A. and Lander,E.S. (2007) The
mammalian epigenome. Cell, 128, 669–681.
11. Bock,C. and Lengauer,T. (2008) Computational epigenetics.
Bioinformatics, 24, 1–10.
12. Peaston,A.E. and Whitelaw,E. (2006) Epigenetics and phenotypic
variation in mammals. Mamm. Genome, 17, 365–374.
13. Wong,A.H., Gottesman,II and Petronis,A. (2005) Phenotypic
diﬀerences in genetically identical organisms: the epigenetic
perspective. Hum. Mol. Genet., 14, R11–R18.
14. Mikeska,T., Bock,C., El-Maarri,O., Hu ¨ bner,A., Ehrentraut,D.,
Schramm,J., Felsberg,J., Kahl,P., Bu ¨ ttner,R. et al. (2007)
Optimization of quantitative MGMT promoter methylation analysis
using pyrosequencing and combined bisulﬁte restriction analysis.
J. Mol. Diagn., 9, 368–381.
15. Eckhardt,F., Lewin,J., Cortese,R., Rakyan,V.K., Attwood,J.,
Burger,M., Burton,J., Cox,T.V., Davies,R. et al. (2006) DNA
methylation proﬁling of human chromosomes 6, 20 and 22. Nat.
Genet., 38, 1378–1385.
16. Tabachnick,B.G. and Fidell,L.S. (2007) Using Multivariate
Statistics, 5th edn. Pearson/Allyn & Bacon, Boston.
17. Carninci,P., Sandelin,A., Lenhard,B., Katayama,S., Shimokawa,K.,
Ponjavic,J., Semple,C.A., Taylor,M.S., Engstro ¨ m,P.G. et al. (2006)
Genome-wide analysis of mammalian promoter architecture and
evolution. Nat. Genet., 38, 626–635.
18. Shen,L., Kondo,Y., Guo,Y., Zhang,J., Zhang,L., Ahmed,S., Shu,J.,
Chen,X., Waterland,R.A. et al. (2007) Genome-wide proﬁling of
DNA methylation reveals a class of normally methylated CpG
island promoters. PLoS Genet., 3, 2023–2036.
19. Lewin,J., Schmitt,A.O., Adorjan,P., Hildmann,T. and
Piepenbrock,C. (2004) Quantitative DNA methylation analysis
based on four-dye trace data from direct sequencing of PCR
ampliﬁcates. Bioinformatics, 20, 3005–3012.
20. Turker,M.S. (2002) Gene silencing in mammalian cells and the
spread of DNA methylation. Oncogene, 21, 5388–5393.
21. Handa,V. and Jeltsch,A. (2005) Profound ﬂanking sequence
preference of Dnmt3a and Dnmt3b mammalian DNA
methyltransferases shape the human epigenome. J. Mol. Biol., 348,
1103–1112.
22. Xu,J., Pope,S.D., Jazirehi,A.R., Attema,J.L., Papathanasiou,P.,
Watts,J.A., Zaret,K.S., Weissman,I.L. and Smale,S.T. (2007)
Pioneer factor interactions and unmethylated CpG dinucleotides
mark silent tissue-speciﬁc enhancers in embryonic stem cells.
Proc. Natl Acad. Sci. USA, 104, 12377–12382.
23. Weber,M., Hellmann,I., Stadler,M.B., Ramos,L., Pa ¨ a ¨ bo,S.,
Rebhan,M. and Schu ¨ beler,D. (2007) Distribution, silencing
potential and evolutionary impact of promoter DNA methylation in
the human genome. Nat. Genet., 39, 457–466.
24. Laird,P.W. (2005) Cancer epigenetics. Hum. Mol. Genet., 14,
R65–R76.
25. Sontag,L.B., Lorincz,M.C. and Luebeck,E.G. (2006) Dynamics,
stability and inheritance of somatic DNA methylation imprints.
J. Theor. Biol., 242, 890–899.
26. Dodd,I.B., Micheelsen,M.A., Sneppen,K. and Thon,G. (2007)
Theoretical analysis of epigenetic cell memory by nucleosome
modiﬁcation. Cell, 129, 813–822.
27. Meissner,A., Gnirke,A., Bell,G.W., Ramsahoye,B., Lander,E.S. and
Jaenisch,R. (2005) Reduced representation bisulﬁte sequencing for
e55 Nucleic Acids Research, 2008, Vol. 36, No. 10 PAGE 10 OF11comparative high-resolution DNA methylation analysis. Nucleic
Acids Res., 33, 5868–5877.
28. Huang,T.H., Perry,M.R. and Laux,D.E. (1999) Methylation
proﬁling of CpG islands in human breast cancer cells. Hum. Mol.
Genet., 8, 459–470.
29. Khulan,B., Thompson,R.F., Ye,K., Fazzari,M.J., Suzuki,M.,
Stasiek,E., Figueroa,M.E., Glass,J.L., Chen,Q. et al. (2006)
Comparative isoschizomer proﬁling of cytosine methylation: the
HELP assay. Genome Res., 16, 1046–1055.
30. Pﬁster,S., Schlaeger,C., Mendrzyk,F., Wittmann,A., Benner,A.,
Kulozik,A., Scheurlen,W., Radlwimmer,B. and Lichter,P. (2007)
Array-based proﬁling of reference-independent methylation status
(aPRIMES) identiﬁes frequent promoter methylation and
consecutive downregulation of ZIC2 in pediatric medulloblastoma.
Nucleic Acids Res., 35, e51.
31. Rollins,R.A., Haghighi,F., Edwards,J.R., Das,R., Zhang,M.Q.,
Ju,J. and Bestor,T.H. (2006) Large-scale structure of genomic
methylation patterns. Genome Res., 16, 157–163.
32. Weber,M., Davies,J.J., Wittig,D., Oakeley,E.J., Haase,M.,
Lam,W.L. and Schu ¨ beler,D. (2005) Chromosome-wide and
promoter-speciﬁc analyses identify sites of diﬀerential DNA
methylation in normal and transformed human cells. Nat. Genet.,
37, 853–862.
33. Zhang,X., Yazaki,J., Sundaresan,A., Cokus,S., Chan,S.W.,
Chen,H., Henderson,I.R., Shinn,P., Pellegrini,M. et al. (2006)
Genome-wide high-resolution mapping and functional analysis of
DNA methylation in arabidopsis. Cell, 126, 1189–1201.
34. Zilberman,D., Gehring,M., Tran,R.K., Ballinger,T. and Henikoﬀ,S.
(2007) Genome-wide analysis of Arabidopsis thaliana DNA
methylation uncovers an interdependence between methylation and
transcription. Nat. Genet., 39, 61–69.
35. Adorjan,P., Distler,J., Lipscher,E., Model,F., Mu ¨ ller,J., Pelet,C.,
Braun,A., Florl,A.R., Gutig,D. et al. (2002) Tumour class predic-
tion and discovery by microarray-based DNA methylation analysis.
Nucleic Acids Res., 30, e21.
36. Gitan,R.S., Shi,H., Chen,C.M., Yan,P.S. and Huang,T.H. (2002)
Methylation-speciﬁc oligonucleotide microarray: a new potential for
high-throughput methylation analysis. Genome Res., 12, 158–164.
37. Kimura,N., Nagasaka,T., Murakami,J., Sasamoto,H.,
Murakami,M., Tanaka,N. and Matsubara,N. (2005) Methylation
proﬁles of genes utilizing newly developed CpG island
methylation microarray on colorectal cancer patients. Nucleic Acids
Res., 33, e46.
38. Yan,P.S., Wei,S.H. and Huang,T.H. (2004) Methylation-speciﬁc
oligonucleotide microarray. Methods Mol. Biol., 287, 251–260.
39. Rakyan,V.K., Hildmann,T., Novik,K.L., Lewin,J., Tost,J.,
Cox,A.V., Andrews,T.D., Howe,K.L., Otto,T. et al. (2004) DNA
methylation proﬁling of the human major histocompatibility
complex: a pilot study for the human epigenome project. PLoS
Biol., 2, e405.
PAGE 11 OF11 Nucleic Acids Research, 2008, Vol. 36, No. 10 e55